Travere Therapeutics, Inc. (TVTX) stock
TVTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 6/30751% above fair value
$51.10+1.40 (+2.82%)
Close on Nov 17, 2026Market cap $4.82BP/E –Yield –
Travere Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Travere Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $227.14M, up 8.2% year over year. For fiscal 2026 it was $206.01M, down 5.3% from the year before. Over ten years it grew 15.1% a year on average. The highest annual figure on record is $244.99M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Dec 31, 2025 | $206.01M | -5.3% |
| FY2025 | Dec 31, 2024 | $217.50M | -11.2% |
| FY2024 | Dec 31, 2023 | $244.99M | +7.8% |
| FY2023 | Dec 31, 2022 | $227.33M | +13.0% |
| FY2022 | Dec 31, 2021 | $201.16M | +52.7% |
| FY2021 | Dec 31, 2020 | $131.77M | -6.5% |
| FY2020 | Dec 31, 2019 | $140.96M | +13.9% |
| FY2019 | Dec 31, 2018 | $123.76M | +58.3% |
| FY2018 | Dec 31, 2017 | $78.17M | +10.4% |
| FY2017 | Dec 31, 2016 | $70.82M | +40.4% |
| FY2016 | Dec 31, 2015 | $50.43M | +5.5% |
| FY2015 | Dec 31, 2014 | $47.80M | +574.7% |
| FY2014 | Dec 31, 2013 | $7.08M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027 | Jun 30, 2026 | $60.28M | +22.1% |
| Q1 FY2027 | Mar 31, 2026 | $57.09M | +21.8% |
| Q4 FY2026 | Dec 31, 2025 | $57.87M | -6.8% |
| Q3 FY2026 | Sep 30, 2025 | $51.89M | +0.4% |
| Q2 FY2026 | Jun 30, 2025 | $49.36M | -9.1% |
| Q1 FY2026 | Mar 31, 2025 | $46.89M | -5.1% |
| Q4 FY2025 | Dec 31, 2024 | $62.07M | +3.9% |
| Q3 FY2025 | Sep 30, 2024 | $51.68M | -14.7% |
| Q2 FY2025 | Jun 30, 2024 | $54.33M | -18.3% |
| Q1 FY2025 | Mar 31, 2024 | $49.42M | -15.0% |
| Q4 FY2024 | Dec 31, 2023 | $59.75M | +2.9% |
| Q3 FY2024 | Sep 30, 2023 | $60.59M | +6.0% |
| Q2 FY2024 | Jun 30, 2023 | $66.49M | +11.4% |
| Q1 FY2024 | Mar 31, 2023 | $58.16M | +2.7% |
| Q4 FY2023 | Dec 31, 2022 | $58.09M | +9.6% |
| Q3 FY2023 | Sep 30, 2022 | $57.15M | +18.1% |
| Q2 FY2023 | Jun 30, 2022 | $59.68M | +15.2% |
| Q1 FY2023 | Mar 31, 2022 | $56.61M | +18.1% |
| Q4 FY2022 | Dec 31, 2021 | $53.00M | +38.1% |
| Q3 FY2022 | Sep 30, 2021 | $48.41M | +49.6% |
| Q2 FY2022 | Jun 30, 2021 | $51.81M | +68.3% |
| Q1 FY2022 | Mar 31, 2021 | $47.95M | +58.5% |
| Q4 FY2021 | Dec 31, 2020 | $38.39M | +5.6% |
| Q3 FY2021 | Sep 30, 2020 | $32.35M | -2.6% |
| Q2 FY2021 | Jun 30, 2020 | $30.79M | -18.8% |
| Q1 FY2021 | Mar 31, 2020 | $30.25M | -9.6% |
| Q4 FY2020 | Dec 31, 2019 | $36.37M | +12.9% |
| Q3 FY2020 | Sep 30, 2019 | $33.22M | +2.4% |
| Q2 FY2020 | Jun 30, 2019 | $37.93M | +10.1% |
| Q1 FY2020 | Mar 31, 2019 | $33.44M | +35.7% |
| Q4 FY2019 | Dec 31, 2018 | $32.21M | +64.6% |
| Q3 FY2019 | Sep 30, 2018 | $32.45M | +65.5% |
| Q2 FY2019 | Jun 30, 2018 | $34.46M | +76.9% |
| Q1 FY2019 | Mar 31, 2018 | $24.64M | +18.1% |
| Q4 FY2018 | Dec 31, 2017 | $19.58M | -2.4% |
| Q3 FY2018 | Sep 30, 2017 | $19.61M | +6.5% |
| Q2 FY2018 | Jun 30, 2017 | $19.48M | – |
| Q1 FY2018 | Mar 31, 2017 | $20.86M | – |
| Q4 FY2017 | Dec 31, 2016 | $20.06M | – |
| Q3 FY2017 | Sep 30, 2016 | $18.41M | – |
See a number that looks wrong?